By selling US$152k worth of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) stock at an average sell price of US$1.06 over the last year, insiders seemed to have made the most of their holdings. The company's market worth decreased by US$9.1m over the past week after the stock price dropped 11%, although insiders were able to minimize their losses
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
The Last 12 Months Of Insider Transactions At PMV Pharmaceuticals
Over the last year, we can see that the biggest insider sale was by the Co-Founder, David Mack, for US$62k worth of shares, at about US$1.06 per share. That means that an insider was selling shares at slightly below the current price (US$1.39). We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 6.1% of David Mack's holding.
Insiders in PMV Pharmaceuticals didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
See our latest analysis for PMV Pharmaceuticals
I will like PMV Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
Insider Ownership
Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Based on our data, PMV Pharmaceuticals insiders have about 3.4% of the stock, worth approximately US$2.6m. We consider this fairly low insider ownership.
So What Does This Data Suggest About PMV Pharmaceuticals Insiders?
It doesn't really mean much that no insider has traded PMV Pharmaceuticals shares in the last quarter. We don't take much encouragement from the transactions by PMV Pharmaceuticals insiders. And usually insiders own more stock in the company, according to our data. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 4 warning signs for PMV Pharmaceuticals you should be aware of, and 1 of them is significant.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.